SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending amid discussions about potential defense contracts, particularly related to the "Golden Dome" initiative, which is a proposed multi-layered missile defense system designed to protect the U.S. Some investors believe $LASR could be a key player, similar to $PLTR, and community members are setting high sell orders to prevent share borrowing by shorts. There's also chatter around technical analysis, potential breakouts, and previous earnings performance driving the stock's momentum.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as discussions revolve around the potential of its Greenland project and its role in securing critical mineral supply chains, particularly with recent drilling results highlighting multi-commodity potential. The community is actively discussing the implications of the project's resources, including zirconium, tantalum, yttrium, and cerium, for various high-tech applications. Community members are also weighing the potential for government stakes and how the company fits into the broader context of Western nations reducing reliance on Chinese mineral resources.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending downwards, with community chatter focused on a sharp sell-off despite recent earnings and analyst upgrades, generating discussions around potential support levels and oversold conditions. Concerns over AI revenue specifics and margin impacts, as well as broader market rotation, are cited as possible catalysts. Some traders speculate about market manipulation, while others remain bullish, citing the company's AI backlog and potential for a rebound.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with the community discussing the potential for further declines and key support levels, possibly driven by overall market concerns and sector-specific headwinds related to data center profitability. Investors are debating whether the recent drop represents a buying opportunity or a sign of deeper issues, with discussions around the company's fundamentals versus market sentiment. The conversation includes mentions of AI bubble fears, tax-loss harvesting, and potential rate hikes, adding to the uncertainty surrounding the stock.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its explosive move and massive after-hours continuation, with the community actively discussing overnight trading and potential price targets. The stock, a robotics de-SPAC, is drawing attention as traders assess its potential in the robotics theme, despite some mixed sentiment in the sector. Discussions also revolve around possible short squeezes and comparisons to other high-flying stocks.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as optimism grows around its AI and autonomous driving initiatives, particularly after unveiling its custom AI chip. The community is discussing the potential for Rivian to become a leader in software-defined vehicles, challenging Tesla's dominance. Broader market interest is buoyed by Needham's boosted price target and overall positive sentiment for EV growth names.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock tests new 2025 highs, driven by ongoing autonomous driving tests and excitement around potential robotaxi deployment; the community is debating whether the current valuation is justified, considering future growth prospects versus current fundamentals. Discussions also include potential impacts from Elon Musk's other ventures like SpaceX.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community aims to revive "OG Memes" and the spirit of 2021, driven by bullish market sentiment and discussions around exchange listings. Community members are actively highlighting the strong community, potential for growth, and the ongoing efforts to build and innovate within the meme space. The focus remains on conviction, community ownership, and a return to the roots of internet meme culture.

$WORKIE is the official workers memecoin on Base.

Workie

Workie crypto is gaining attention as community members actively promote the token and share contract addresses. The community emphasizes the potential for financial independence, envisioning a future free from traditional work. Ongoing discussions focus on increasing visibility and encouraging further investment in Workie.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

Artiva Biotherapeutics ($ARTV) is trending due to receiving FDA Fast Track designation for its AlloNK therapy in refractory rheumatoid arthritis, sparking significant investor interest. The community is discussing the potential for accelerated development and market entry, along with analyst upgrades and price targets. High trading volume and positive early clinical data are further fueling the conversation around ARTV's potential in the autoimmune disease space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat Ratings...

Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average...

Fred Aslan Sells 6,375 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average...

HC Wainwright Forecasts Strong Price Appreciation for Artiva Biotherapeutics (NASDAQ:ARTV) Stock

HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday...

Artiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus...

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Equity

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.


Current Price	$6.34
Prev Close	$3.30
Open	$4.09
Dividend Yield	0.00%
50-Day Moving Average	$3.69
Beta	1.40
Avg. Volume	196,447.53
PE Ratio	-1.94

52-Week High	$11.55
52-Week Low	$1.47
Market Capitalization	$81M
EPS (Annual)	-$2.69
Price to Book	1.20
Revenue Per Employee	$2,820.22
Enterprise Value/EBITDA	N/A

ARTV
Artiva Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARTV News

ARTVArtiva Biotherapeutics Inc